Emmaus Life Sciences announced that it has received Registration Approval from the Pharmaceutical and Herbal Medicines Registration and Control Administration of the Kuwaiti Ministry of Health, granting marketing authorization for the commercial distribution and sale of Endari in the country. "Kuwait is the latest Gulf Cooperation Council country to grant full marketing approval for Endari following approvals in the United Arab Emirates and the State of Qatar earlier this year. Endari is approved in the U.S. and elsewhere to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari is available on an early access basis in Bahrain and the Kingdom of Saudi Arabia pending official notice of action on Emmaus’s marketing authorization applications in those countries," the company stated.
Published first on TheFly
